Commit Biologics funding news – Denmark-based Commit Biologics launches with €16Million in Seed Funding

A powerful and quickly acting component of the innate immune system. With the use of antibodies, the modular BiCETM system may steer the complement system in a highly targeted manner, killing cancer cells or immune cells that cause autoimmune illnesses.

Read also - Axmed funding news – Healthtech Marketplace Axmed Secures $2 Million in Seed Funding

Commit is a spin-out of Aarhus University in Denmark, which over the past three decades has established itself as a world-renowned centre of research in complement system biology. The BioInnovation Institute in Denmark provided early incubation and assistance for the company.

Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: "This financing from Novo Holdings and Bioqube Ventures validates our pioneering approach of engaging and activating the complement system for therapeutic purposes. Our BiCE™ platform gives us the ability to engage the complement system so that it attacks targeted cells in a highly selective manner. This platform also means we can use established antibodies, which cuts development times and reduces risk, to develop best-in-class therapeutics. This is a novel way of harnessing the immune system to tackle cancer and autoimmune disease, and we are confident in the tremendous potential it offers."

Jeroen Bakker, Partner at Novo Holdings, said: "With over 30 years of academic rigor from leaders in the complement field behind it, Commit is now unlocking the potential of the complement system to transform the fight against cancer and autoimmune diseases. The team has an incredible track record of domain expertise, and we look forward to working with them to support them on their journey."

Roderick Verhelst, Principal at Bioqube Ventures, said: "We believe Commit is doing something truly novel in the field of complement and advancing a technology with a multitude of therapeutic applications. Through its direct engagement of the complement system, this BiCE™ technology is a best-in-class approach for complement activation. The ability to arm conventional antibodies with potent complement activators for the development of targeted cell killing therapeutics is also a very attractive way of accelerating and derisking product development."

About Commit Biologics

Commit Biologics, a company that specialises in cancer and autoimmune illnesses, is a trailblazer in the field of complement system activation with the purpose of killing certain target cells. derived from Aarhus University and based on research conducted over thirty years.

A traditional monoclonal antibody can be enhanced by Commit's Bispecific Complement Engaging (BiCETM) technology to more efficiently engage the complement system. This is accomplished by combining an antibody that binds to a biological target with single domain antibodies that engage C1q, the initiator of the complement activation cascade.